Royal College of Surgeons

Ananda Developments Advances Cannabinoid Medicines in Phase III Epilepsy Trials

7 months ago

• Ananda Developments' MRX2 and MRX2T formulations selected for two Phase III trials targeting drug-resistant epilepsies, funded by NIHR and NHS England. • The trials will assess the safety and efficacy of CBD and CBD+THC in reducing seizure frequency and improving quality of life in 500 patients. • Ananda's MRX1 formulation demonstrates cardioprotective effects in preclinical studies for Heart Fibrosis with Preserved Ejection Fraction (HFpEF). • A Phase 1 pharmacokinetic study of MRX1 is underway in Australia, leveraging R&D tax incentives to support regulatory applications.